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A B S T R A C T   
Circular RNAs (circRNAs) are a class of endogenous noncoding RNA, which were previously considered as a 
byproduct of RNA splicing error. Numerous studies have demonstrated the altered expression of circRNAs in 
organ tissues during pathological conditions and their involvements in disease pathogenesis and progression, 
including cancers. In colorectal cancer (CRC), multiple circRNAs have been identified and characterized as 
“oncogenic”, given their involvements in the downregulation of tumor suppressor genes and induction of tumor 
initiation, progression, invasion, and metastasis. Additionally, other circRNAs have been identified in CRC and 
characterized as “tumor suppressive” based on their ability of inhibiting the expression of oncogenic genes and 
suppressing tumor growth and proliferation. circRNAs could serve as potential diagnostic and prognostic bio-
markers, and therapeutic targets or vectors to be utilized in cancer therapies. This review briefly describes the 
dynamic changes of the tumor microenvironment inducing immunosuppression and tumorigenesis, and outlines 
the biogenesis and characteristics of circRNAs and recent findings indicating their roles and functions in the CRC 
tumor microenvironment. It also discusses strategies and technologies, which could be employed in the future to 
overcome current cancer therapy challenges associated with circRNAs.   
1. Introduction 
Colorectal cancer (CRC) is one of the most malignant tumors; the 
third commonly occurring and second leading cause of death globally 
after lung cancer [1]. The incidence and mortality rates of CRC are 
greatly affected by family history, age and lifestyle [2]. Even though 
surgical resection remains the best curative treatment strategy for early 
stage tumor, there is 30–60% chance for relapse which again increases 
the morbidity in CRC patients [3]. Despite of all the current advances in 
cancer therapies, their effectiveness in CRC patients is largely affected 
by the tumor immune microenvironment [4]. Mounting evidence sug-
gest that multiple factors are involved in driving the onset and/or pro-
gression of CRC, including gene mutations, dysregulation in the 
chromosomal-copy number, atypical methylation profile, and 
post-transcriptional modifications, which can all lead to aberrant gene 
expression [5–9]. However, potential significant molecular mechanisms 
behind the development and progression of CRC are still elusive. 
About four decades ago, the first reference of circular RNAs (circR-
NAs) was given as displaced loops of single stranded adenovirus DNA 
[10,11]. Later on, Nigro et al. reported the presence of some unexpected 
arrangements of exons, and called as “scrambled exons”, while studying 
splicing in the tumor suppressor gene DCC (Deleted in colorectal cancer) 
[12]. Over the years, circRNAs were characterized as non-coding 
endogenous RNAs originated from alternate splicing and pre-mRNA 
processing of a large fraction of genes across eukaryotes ranging from 
fruit flies to human [13,14]. Following splicing and pre-mRNA pro-
cessing, single stranded RNA forms circles by covalent binding and 
losing its poly A tail on 3′ end and 5′ caps [15]. Moreover, circRNAs have 
superior stability over linear isoforms, and they are conserved among a 
vast number of species including protists, nematodes and zebrafish [16], 
and abundantly expressed in cells, compared to the level of their linear 
counterparts [17]. However, reports showed that the abundance and 
localization of circRNAs within the cells vary across different cell 
types/conditions [18,19]. For instance, the predominant exonic forms of 
circRNAs leave the nuclei to reside in the cytoplasm, while the minor 
forms that contain introns reside in nuclei [20]. 
Multiple lines of evidence have indicated that circRNAs could 
interfere with the expression of genes to modulate cancer-related 
signaling pathways [21]. It has been shown that altered gene expres-
sion profiles are correlated with tumorigenesis in multiple cancer types 
and can contribute to different aspects of cancer progression [22]. Using 
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high-throughput approaches, researchers have shown that circRNAs are 
differentially expressed in various malignancies, including CRC [23]. 
CircRNAs are stable, abundant, and can be easily detected and quanti-
fied in samples, such as blood, urine and saliva, which enable their 
potential use as ideal biomarkers for cancer diagnosis and prognosis 
[24]. 
The crosstalk between circRNAs and components of the tumor 
microenvironment (TME) is becoming a hot spot for the researchers in 
the cancer field. Deciphering such an interplay will help in establishing 
the role of circRNAs in cancer, and understanding their contribution to 
the development of resistance to cancer therapy [25]. The nature of the 
TME has a great influence on the invasiveness, metastatic potential of 
the tumor as well as the emergence of drug resistance in multiple cancer 
settings including CRC [26–28]. Further investigations on the involve-
ment of circRNAs in the colorectal TME may provide plausible discovery 
of novel biomarkers and therapeutic targets in CRC patients [24]. 
Furthermore, targeting circRNAs in the colorectal TME may accomplish 
greater therapeutic efficacy than current therapeutic modalities. 
2. The tumor microenvironment 
The TME of solid tumors like CRC consists of multiple cell types, such 
as immune cells, tumor cells, endothelial and stromal cells, and creates a 
complex suppressive network enabling cell-to-cell interactions favoring 
tumor survival, growth and metastasis [27]. These dynamic interactions 
are crucial for the heterogeneity, clonal development, drug resistance 
and metastasis of malignant cells [27,29]. Tumor cells release various 
chemokines and cytokines to promote the trafficking of suppressive 
immune cells, such as myeloid-derived suppressive cells (MDSCs) and T 
regulatory cells, into the TME and induce the conversion of fibroblasts 
into cancer-associated fibroblasts (CAFs), which in turn support tumor 
growth and progression and suppress effector T cell function and pro-
liferation [27,29]. 
The composition and nature of the TME can be modulated by mul-
tiple genetic, epigenetic, and metabolic factors, and immunosuppressive 
mechanisms acquired during the progression of cancer or upon thera-
peutic interventions [9,27,28]. Therefore, a deep understanding of the 
molecular, cellular, and metabolic characteristics of the TME is vital to 
reveal the underlying mechanisms driving such effects, and to determine 
the therapeutic outcomes in cancer patients [30]. Indeed, numerous 
therapeutic modalities fail to show clinical efficacy in targeting tumor 
cells due to the dynamic changes within the TME. This urges the need to 
perform further investigations to gain better understanding of the TME 
and pathological mechanisms, which can potentially further our un-
derstanding of immune regulation, identify diagnostic and prognos-
tic/predictive biomarkers to ease the screening/diagnosis of cancers, 
predict disease outcomes in response to therapy and distinguish re-
sponders and non-responders. Additionally, more focused research can 
potentially identify candidates for novel therapeutic targets to improve 
clinical outcomes in cancer patients. 
3. Classification and biogenesis of circular RNAs 
Based on the composition of circRNAs, they are classified into four 
categories; (i) RNA circles transcribed from exon, termed as Exonic 
circRNAs (ecircRNAs) [17], (ii) one or more exons with flanking introns 
forms Exon-Intron circRNAs (EIcircRNAs) [19], (iii) circRNAs derived 
solely from intronic region of pre-mRNA are intronic circRNAs or ciR-
NAs [31] (iv) circRNAs formed from intron of pre-tRNA called transfer 
RNA (tRNA) intronic circular RNAs (tricRNAs) [32]. There are three 
models explaining the biogenesis of the dominant class exonic circRNAs 
in eukaryotes (Fig. 1); (i) lariat-driven circularization/exon skipping 
[33], (ii) intron-pairing driven circularization/back splicing [34], and 
(iii) RNA binding protein (RBP)-driven circularization [35]. 
In eukaryotes, canonical spliceosome removes introns from pre- 
mRNA and joins the exons to form linear mRNA of 5′ to 3′ polarity by 
a splicing reaction which can be summarized in two steps; (i) the 2′ OH 
group of adenosine residue at the branch point within the intron attracts 
nucleotide at 5′ splice site and forms a 2′–5′ phosphodiester bond to 
release the intron lariat, and (ii) the free 3′ OH group released upon 2′–5′
phosphodiester formation attracts 5′ splice site of downstream exon 
resulting in the joining of exons by a 3′–5′ phosphodiester bond [36]. In 
exon skipping model, the excised intron lariat containing one or more 
skipped exons proceeds to internal splicing giving rise to circRNAs [15]. 
Whereas in intron-pairing driven circularization, base pairing occurs 
between introns due to inverted repeats, followed by back splicing to 
join 3′ and 5′ splice sites resulting in the formation of circRNA. In both 
events, intron may or may not be retained to form either EIcircRNAs or 
ecircRNAs, respectively [13]. Instead of base pairing, RBPs also act as a 
bridge to shorten the distance between donor and recipient splice sites of 
Nomenclature 
APC Adenomatous polyposis coli 
BCL2 B-cell lymphoma 2 
CDK Cyclin dependent kinase 
CDRI Cerebellar degeneration related protein 1 
ceRNA Competing endogenous RNA 
circRNA Circular RNA 
ciRNA Circular intronic RNA 
CRC Colorectal cancer 
ecircRNA Exonic circular RNA 
EGF epidermal growth factor 
EGFR Epidermal growth factor receptor 
EIcircRNA Exon-intron circRNA 
EMT Epithelial to mesenchymal transition 
ERK Extracellular signal-regulated kinase 
HCC Hepatocellular carcinoma 
ICS Inverted complementary repeats 
IRES Ribosome entry site (IRES) 
m6A N6-methyl adenosine 
MAPK Mitogen-activated protein kinase 
MDM2 Mouse double minute 2 homolog 
MDSC Myeloid derived suppressor cell 
MREs miRNA response elements 
miRNA Micro-RNA 
ORF Open reading frame 
PD-1 Programmed cell death receptor-1 
PD-L1 Programmed death ligand-1 
PI3K Phosphatidylinositol 3-kinase 
PKB Protein kinase B 
Pre-mRNA Premature messenger RNA 
Pre-tRNA Premature transfer RNA 
TERT Telomerase reverse transcriptase 
Tiam1 T lymphoma invasion and metastasis protein 1 
TME Tumor microenvironment 
TP53 Tumor protein P53 
TSEN tRNA splicing endonuclease 
tricRNA tRNA intronic circular 
RBPs RNA binding proteins 
RNA Pol II RNA polymerase II 
Sry Sex determining region Y 
Tregs T regulatory cells 
VEGF-A Vascular endothelial growth factor-A 
ZEB1 Zinc finger E-box binding homeobox 1  
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flanking introns, followed by back splicing to form ecircRNAs [35]. It 
has also been reported that ciRNAs are formed by the splicing reaction 
between the 11 nucleotide GU rich element at 5′ splice site and 7 
nucleotide C rich element at 3′ branch point on the introns [31]. 
Notably, tRNA splicing endonuclease (TSEN) cleaves pre-tRNA at the 
splicing motif to release the tricRNAs by direct ligation [37]. 
The expression of circRNA is well-regulated and dependent on gene, 
cell, and tissue type [19]. At the gene level, circRNA biogenesis depends 
on the number and length of exons and introns and enrichment of splice 
sites [38]. Later, the expression of circRNA is regulated during gene 
transcription where pre-mRNA is formed. Of note, several cis and trans 
acting elements can control back splicing efficiency and the biogenesis 
of circRNAs [38]. In addition to this, the availability of several others 
factors like RBPs, spliceosomal proteins, and ICS can affect their 
biogenesis [39]. Altered expression of circRNAs affects several down-
stream pathways and finally leads to pathological conditions as it will be 
described in the sections below. 
4. Functions of circular RNAs in cancer 
CircRNAs regulate tumorigenesis and cancer progression through 
epigenetic modulation of gene expression by various mechanisms 
(Fig. 1). To begin, circRNAs act as competing endogenous RNAs (ceR-
NAs) which sponge microRNAs (miRNAs) and interfere with their 
functions leading to aberrant expression of their target genes [40,41] 
(Fig. 1A). The presence of miRNA response elements (MREs) was first 
identified in circRNA derived from CDR1 (cerebellar 
degeneration-related protein 1) gene in brain cells, which has 70 miRNA 
binding sites and has been implicated in many carcinomas [42]. The 
circRNA homeodomain-interacting protein kinase 3 (circHIPK3) 
sponges many miRNAs related with progression of various malignancies 
including lung and ovarian cancers [43,44]. Alternatively, circRNAs can 
bind to proteins and negatively affect the expression of several onco-
genes and tumor suppressor genes such as MYC proto-oncogene, TP53 
(tumor protein P53) and BCL2 (B-cell lymphoma 2) [45]. For instance, 
the circRNA Zinc Finger with KRAB and SCAN Domains 1 (circZKS-
CAN1) competitively binds to RBP-FMRP (fragile X mental retardation 
protein) and inhibits cell proliferation in liver cancer [46]. Additionally, 
circRNAs can act as scaffolder by bringing the proteins and their targets 
closer to enhance their interaction (Fig. 1B). For instance, the circRNA 
Forkhead Box O3 (circFOXO3) can form a complex with p21 and CDK2 
(cyclin dependent kinase 2), which retards cell survival and prolifera-
tion and induces apoptosis in several carcinomas and leukemias 
[47–49]. Besides this, circFOXO3 can interact with MDM2 (mouse 
double minute 2 homolog; also known as E3 ubiquitin-protein ligase) to 
facilitate ubiquitination and degradation of p53, which is a classical 
pathway in tumorigenesis [50,51]. However, the protein binding ca-
pacity of circRNAs depends on their unique tertiary structure and are 
more complex compared to linear RNAs [52]. Furthermore, circRNAs 
can be encapsulated in exosomes, which are small diameter vesicles 
originated from endosomes and formed from donor cells then fused into 
recipient cells [53,54]. This enables the transfer of exosomal circRNAs to 
distant sites where they exert tumor-promoting or tumor-suppressive 
functions [54] (Fig. 1C). Wang et al. demonstrated that exosomes 
derived from high metastatic hepatocellular carcinoma (HCC) cells are 
enriched with exosomal circPTGR1 (circRNA Prostaglandin Reductase 
1), which can increase capacity of tumor cell migration and invasion and 
ultimately lead to the progression of HCC [55]. Additionally, exosomal 
circRNAs in body fluids, such as plasma, serum, urine, synovial fluid and 
cerebrospinal fluid, can also serve as diagnostic or prognostic bio-
markers in cancer and can influence host anti-tumor immunity and 
response to cancer therapy [54]. For instance, Chen et al. reported that 
immunosuppression in metastatic melanoma patients is associated with 
high levels of circulating exosomal PD-L1 (programmed death ligand-1), 
Fig. 1. Biogenesis of circRNA. (i) Lariat-driven 
circularization: during splicing, exon skipping 
results in the formation of lariat containing in-
trons and exons, which further undergoes in-
ternal splicing to yield EIcircRNA. (ii) Intron- 
pairing driven circularization: the 3′ and 5′
splice sites are joined by base pairing between 
the inverted complementary repeats (ICS) pre-
sent in intron followed by back splicing to give 
rise to EIcircRNA. (iii) RNA binding protein 
(RBP)-driven circularization: splice sites are 
brought close to each other by RBP and form 
ecircRNA or EIcircRNA. (iv) Circular intronic 
RNA (ciRNA) is formed by the direct ligation of 
GU rich and C rich elements on the introns. (v) 
Special tRNA splicing enzyme cleaves intronic 
region of pre-tRNA, which is later ligated by a 
3′–5′ phosphodiester bond to form tricRNA. 
Functions of circRNA: (A) circRNA binds and 
removes target miRNA to modulate the 
expression of target gene. (B) circRNA acts as a 
protein decoy or protein scaffolder either to 
bring the proteins and their targets close 
together to enhance their interaction or facili-
tate their proteasomal degradation. (C) circRNA 
is transferred through exosomes to distant sites 
where it carries out its specific function. (D) 
circRNA also encodes for a protein product 
through cap-independent translation initiation 
mechanisms. (E) circRNA enhances the rate of 
transcription through the interaction with RNA 
pol II.   
J. Viralippurath Ashraf et al.                                                                                                                                                                                                                 
Biomedicine & Pharmacotherapy 137 (2021) 111351
4
which can predict the response to anti-PD-1 (programmed cell death 
receptor-1) therapy [56]. 
Exonic circRNA present in the cytoplasm can also serves as templates 
to be translated into proteins through cap-independent translation 
initiation mechanism (Fig. 1D) as they contain internal ribosome entry 
site (IRES) and open reading frame (ORF) [57,58]. Studies have shown 
that the first identified protein coding circRNA in mouse myoblast, 
circZNF609, is translated in a cap independent manner using IRES [59, 
60]. Functions of circZNF609 include the facilitation of myogenesis and 
G1-S progression in rhabdomyosarcoma by upregulating cell-cycle 
related genes [61], and stimulation of cell proliferation and migration 
in several carcinoma including glioma, and gastric and breast cancers 
[62–64]. On the contrary, circZNF609 acts as a tumor suppressor in CRC 
by upregulating p53 and promoting apoptosis [65]. Currently, multiple 
circRNAs including circSHPRH, circAKT3, circβ-catenin, circLgr4, and 
circPPP1R12A encode proteins have been shown to involved in the 
regulation of cell proliferation, migration/invasiveness, and 
self-renewal in different cancer settings [66–70]. For instance, 
circSHPRH, encodes SHPRH-146aa protein and has been shown to 
inhibit malignancy and tumorigenesis through the ubiquitination of 
proliferating cell nuclear antigen (PCNA) in glioblastoma [66]. Notably, 
other findings have shown that a common base modification of 
N6-methyladenosine (m6A) in RNA is capable of driving protein trans-
lation of circRNAs in human [71]. For instance, expression profile 
analysis has shown that a large fraction of circRNAs with m6A modifi-
cation like circMART3 were translatable [71]. Finally, circRNAs act as 
trans acting elements to interact with several transcription factors and 
enzymes to enhance transcription [72]. For instance, circEIF3J and 
circPAIP2 present in the nucleus as EIcircRNAs can increase the tran-
scription of the parental gene by interacting with RNA Pol II and tran-
scription factors [73]. The interaction of circRNAs with transcription 
factors are depicted in Fig. 1E. Thus, the identification of circRNAs along 
with their downstream targets and their functions can further our un-
derstanding of the molecular and cellular mechanisms driving disease 
pathogenesis and progression, which could be of interest to develop new 
therapeutics and achieve favorable outcomes in cancer patients. 
5. Expression and role of circRNAs in colorectal cancer 
Transcriptomic profiling of circRNA indicates that several circRNAs 
are differentially expressed in tumor tissue, compared to normal tissue. 
For instance, circITGA7 is downregulated in CRC tumor tissues and cell 
lines, and it is involved in the suppression of cell proliferation and 
metastasis by inhibiting Ras pathway through increased expression of its 
host gene ITGA7 [74]. Elevated expression of other tumor suppressive 
circRNAs such as circITCH, circDDX17, circFBXW7 and circCSE1L, have 
been also implicated in the suppression of cell proliferation and 
metastasis and were positively correlated with favorable prognosis in 
CRC patients [75–78]. Conversely, prominent circRNAs including 
circ_0000069, circ_0007843, circCCDC66, circHIPK3, circ_0020397 and 
circBANP are upregulated in colon cancer and promote the proliferation 
and migration of malignant cells [79–84]. The list of oncogenic and 
tumor suppressive circRNAs and their biological roles in CRC are sum-
marized in Tables 1 and 2. 
CircRNAs can potentially mediate stemness and metastasis in CRC 
through exosomes [85]. For instance, exosomes from CD133+ cells carry 
circABCC1 and regulate CRC progression through activation of 
Wnt/β-catenin pathway [85]. Notably, the abundancy of circRNA is 
lower in colon cancer cell lines. This could be due to the distribution of 
circRNAs to daughter cells during the faster cell division [86]. Similarly, 
the abundancy and size of circRNAs were considerably inhibited in 
metastatic tumors, compared with primary tumors [87]. Exosomal 
circRNAs have also the potential for being diagnostic biomarkers to ease 
the screening and detection of CRC. For example, Pan et al. reported that 
serum exosomal circRNA, hsa-circ-0004771, is a novel diagnostic 
biomarker in CRC patients and its over-expression in the circulation of 
CRC patients is tumor-driven as evidenced by the downregulation of its 
expression in CRC patients post tumor resection [88]. Another study by 
Xie et al. identified serum exosomal circ-PNN (hsa_circ_0101802) as a 
potential diagnostic biomarker for CRC and suggested its possible 
involvement in CRC pathogenesis [89]. Additionally, a recent systematic 
meta-analyses on CRC patients indicated that the aberrant expression of 
circRNAs was closely associated with clinicopathological features and 
prognosis of CRC [90]. Altogether, these data underline the diagnostic 
and prognostic potential of circRNAs in CRC. Profiling patient samples 
Table 1 





Biological effect Reference 
circBANP BANP p-Akt Promotes cell 
proliferation 
[84] 
circACAP2 ACAP2 miR-21 Enhances tumor cell 
proliferation and 
invasion through the 
upregulation of Tiam1 
gene 
[153] 
circ_0020397 DOCK1 miR-138 Immune regulation [83] 
circHIPK3 HIPK3 miR-637 Drug resistance [135]   
miR-7 Regulates cell growth 
and proliferation 
[82] 




[154]   




circABCC1 ABCC1 miR-145 Stemness and metastasis [85]    
Gene regulation  
circ_100290  miR-516b Activation of Wnt/ 
β-catenin pathway 
[101] 
ciRS-7 CDR1 miR-7 Activation of EGFR and 
RAF1 oncogenes. 
[104] 
circMDM2 MDM2 P53 Cell cycle progression [107] 
circCTNNA1 CTNNA1 miR-149- 
5p 




circ_0001178  miR-382/ 
587/616 
Upregulates ZEB1 to 
trigger EMT 
[115] 
circPTK2 PTK2  Promotes EMT by 
binding to vimentin on 
serine residue at 38, 55 
and 82 
[116] 
circ_000984 CDK6 miR-106b Tumorigenesis and 
progression 
[155] 














circ_0136666  miR-136/ 
SH2B1 
Cell cycle transition G0/ 
G1 phase 
[157] 






circ_0136666  miR-136 SH2B1 upregulation and 
cell cycle progression at 
G0/G1 
[157] 
circ_0000069 STIL  Mediates G0/G1 
transition 
[79] 
circ_0000231  miR-502- 
5p 
Upregulates Myosin VI 
and promotes glycolysis 
[159] 
circ_0007843  miR-518c- 
5p 





circVAPA VAPA miR-101 Promotes proliferation, 
migration, invasion, and 
inhibits apoptosis 
[117]  
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to characterize and detect the expression of circRNAs and establish an 
array or panel to identify circRNA signature in CRC could be a promising 
approach for developing a non-invasive diagnostic method. Specifically, 
the detection of exosomal circRNAs in plasma can be utilized as a 
straightforward biomarker for diagnosing invasiveness and metastatic 
potential in CRC. 
6. Functions of circRNAs in colorectal TME 
6.1. CircRNAs in the regulation of genome mutations in CRC 
As indicated in several studies, CRC tumorigenesis are closely linked 
to mutations in tumor suppressor genes (TP53 and APC) and KRAS 
(oncogene) [91–94]. Progressive accumulation of these gene mutations 
is a key cause of malignancy in CRC [95]. Until now, the direct 
involvement of circRNAs in inducing mutations of these genes has not 
been confirmed; however, several circRNAs have been associated with 
the altered expression of these genes through epigenetic alterations 
induced by miRNA sponging. For instance, circZNF609 can induce 
apoptosis through the activation of TP53 gene and suppressing CRC 
tumorigenesis [65]. A study by Dou et al. demonstrated that a global 
reduction in circRNAs is closely linked with KRAS mutation in HCT116 
colon cancer cell line [96]. On the contrary, circ_100859 plays a key role 
in CRC development and has been positively associated with KRAS 
mutations [97]. Other studies showed that circRNAs, namely 
circ_009361 and circ-ITCH, inhibit tumorigenesis by upregulating APC 
expression [75,98]. On the other hand, Zhi et al. showed that a trans-
latable circRNA, circLgr4, is elevated in colorectal tumors and colorectal 
cancer stem cells to inhibit APC expression and promote cancer stem cell 
renewal [69]. Further studies are required to confirm the role of circR-
NAs in the induction of genome mutations. Moreover, evaluating the 
nature of mutations induced by circRNAs can accelerate the develop-
ment of novel screening methods for CRC detection. 
6.2. Regulation of tumor growth and progression 
circRNAs can modulate various signaling pathways and cellular 
events in the colorectal TME [21]. Key signaling pathways in cancer 
include mitogen-activated protein kinase (MAPK)/extracellular 
signal-regulated kinase (ERK1/2), phosphatidylinositol 3-kinase 
(PI3K)/protein kinase B (PKB), also known as (AKT), and Wnt/β-cate-
nin pathway [99]. Wnt/β-catenin signaling is the major signaling 
pathway implicated in the pathogenesis/progression and chemo-
resistance of CRC implicated by a mutation in the tumor suppressor gene 
APC (adenomatous polyposis coli) [100]. Fang et al. demonstrated that 
elevated levels of circRNA_100290 in CRC tumor tissues can activate 
Wnt/β-catenin pathway via miR-516b-FZD4 axis, which is positively 
correlated with tumor progression and metastasis [101]. On the con-
trary, circITCH, arise from several exons of the gene encoding itchy E3 
ubiquitin ligase, was downregulated in CRC tissues and has a predom-
inant role in tumor suppression by sponging miR-7, miR-20a, and 
miR-214 to suppress Wnt/β-catenin pathway and ultimately inhibit the 
expression of c-Myc and Cyclin-D1 genes [75]. It has been reported that 
circ_0000523 (also known as circ_006229) is downregulated in CRC cells 
leading to the activation of Wnt/β-catenin signaling and inhibition of 
apoptosis [102]. Additionally, prominent oncogene ciRS-7 is upregu-
lated in CRC tissues, and its function was shown to inhibit epidermal 
growth factor receptor (EGFR) and RAF1/MAPK pathway, which is a 
novel therapeutic target in metastatic CRC [103,104]. 
The aberrant expression of circRNAs is paralleled with sustained cell 
proliferation which is one of the hallmarks of cancer [105]. circRNAs act 
as cis or trans acting elements and interact with transcription factors to 
enhance or repress the rate of parent gene expression. These gene 
products modulate signaling pathways and subsequently regulate cell 
cycle [106]. For instance, circMDM2 can promote proliferation of cancer 
cells by mediating G1/S transition through suppressing the expression of 
p53, which is responsible for inducing cell cycle arrest and apoptosis in 
response to DNA damage [107]. In contrast, circFOXO3 (another p53 
regulator) acts as a tumor suppressor by binding to p21 and CDK2 and 
thereby halting cell cycle [51]. CircHIPK3 upregulates the expression of 
EGFR and IGF1R expression by sponging miR-7 in CRC, promoting 
tumor growth and metastasis [82]. circ_0014717 is downregulated in 
CRC tumor tissues and control tumor cell proliferation by inducing 
G0/G1 cell cycle arrest in vitro [108]. A novel circRNA from CTNNA1 
gene was identified as a regulator for DNA synthesis during S phase, and 
it facilitates G1/S transition to sustain proliferation in CRC [109]. 
Altogether, these reports demonstrate that circRNAs could regulate both 
initiation and termination of cell cycle in CRC. Although it is conclusive 
that circRNAs are key regulators of tumor cell proliferation in CRC, 
deeper understanding of the molecular pathways can lead to targeting 
the responsiveness of circRNAs to mitogens. 
6.3. Induction of epithelial to mesenchymal transition, tumor invasion 
and metastasis 
Epithelial to mesenchymal transition (EMT) is a key biological event 
associated with metastasis, in which epithelial cells become motile and 
attain mesenchymal nature by losing their polarity and anchorage 
[110], accompanied by reduced expression of cell junction proteins like 
E-cadherin and elevated expression of mesenchymal proteins like 
N-cadherin, fibronectin and vimentin [111]. In CRC, EMT is mostly 
activated by modulating signaling pathways including Wnt and Notch 
via transcription factors such as ZEB1 (zinc finger E-box binding ho-
meobox 1) and SNAIL [112,113]. Several circRNAs have been shown to 
act together with transcription factors and play regulatory roles in EMT 
[114]. For instance, circ_0009361 can suppress EMT by sponging 
miR-582 which regulates APC2 expression and inhibit Wnt/β-catenin 
pathway in the colorectal TME [98]. Upregulated levels of circ_0001178 
in CRC cells can activate EMT by upregulating the expression of the 
transcription factor, ZEB1, and sponging miR-382/587/616 which 
Table 2 
Tumor suppressive circRNAs in colorectal cancer.  




Biological function Reference 
circITCH ITCH miR-7 Inhibits Wnt/β-catenin 
pathway 
[75] 
circFBXW7 FBXW7  Upregulates expression of 




circ_000523 METIL3 miR-31/ 
Dkk1 
Inhibits EMT [102] 
circ_0001649 SHPRH  Contributes to pathological 
differentiation 
[160] 
circ_0007534 DDX42  Induces apoptosis [161] 
circDDX17 DDX17 miR-21- 
5p 
Inhibits proliferation and 
induces apoptosis 
[76] 
circ_0060745 CSE1L eIF4A3 Controls cell cycle-related 
factors (Cyclin D1, E1, 
CDK4) 
[78] 
circ_0014717   Upregulates cell cycle 
inhibitory protein p16 
[108] 
circ_0009361  miR-582 Upregulates APC2 
expression and inhibit 
Wnt/β-catenin pathway 
[98] 
circITGA7 ITGA7 miR- 
370-3p 









circ_0026344  miR-183 Represses EMT through 
Wnt/β-catenin pathway 
[163] 
circ_0137008  miR- 
338-5p 
Inhibits EMT [164]  
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subsequently increase N-cadherin expression [115]. Additionally, 
upregulated levels of circPTK2 (also known as circ_0005273) in CRC can 
modulate EMT by binding to phosphorylation sites on vimentin and 
enhance metastasis [116]. Another key regulator of EMT, circ_100290, 
has been shown to inhibit Wnt/β-catenin pathway through sponging 
miR-516b and downregulating FZD4 expression [101]. 
Although the exact molecular mechanisms underlying circRNA 
contribution to tumor metastasis are not fully understood, it is evident 
that altered expression of circRNAs in CRC is associated with tumor 
invasiveness and distant metastasis. It has been reported that high 
expression of circITGA7 in CRC tissues inhibits metastasis through the 
downregulation of Ras signaling pathway and the binding to miR-370- 
3p [74]. On the other hand, Li et al. identified that circVAPA 
(circ_0006990) promotes invasiveness and inhibits apoptosis by binding 
with miR-101-3P [117]. A recent report by Zhang et al. revealed that a 
different regulatory axis of circVAPA acts as a molecular sponge for 
miR-125a to regulate the expression of CREB5 and to promote CRC 
metastasis [118]. Additionally, circCCDC66, which is highly expressed 
in CRC polyp, can enhance anchorage-independent growth of cancer 
cells and act as an oncogene [81]. Another study reported that the 
upregulation of circHUEW1 is positively correlated with 
lympho-vascular invasion and advanced TNM staging [119]. Xu et al. 
indicated that circ_0001178 and circ_0000826 could be used as bio-
markers to detect liver metastasis from CRC tumors [120]. To under-
stand the underlying mechanisms of circRNA contribution to CRC tumor 
metastasis, deeper molecular investigations on tissue samples are 
required rather than comparative studies. 
6.4. Induction of tumor angiogenesis 
Angiogenesis is one of the important hallmarks of cancer and well- 
studied in metastatic CRC [121]. Several angiogenic inhibitors are 
currently used to treat metastatic CRC as they suppresses vascular 
development and tumor progression [122]. Some circRNAs were iden-
tified to regulate angiogenesis through modulating proangiogenic 
agents like epidermal growth factor (EGF) and vascular endothelial 
growth factor-A (VEGF-A) in different angiogenesis-related diseases 
[123]. In CRC, until now, only one circRNA was identified to modulate 
angiogenesis, circ_001971, which was shown to be upregulated in CRC 
tumor tissues and responsible for the upregulation of the proangiogenic 
factor VEGF-A through miR-29c-3p axis [124]. Additionally, it has been 
reported that cancer-derived exosomal miRNAs can promote the 
vascularization and angiogenesis in colon cancer [125]. Nonetheless, 
further investigations are required to explore more angiogenic-related 
circRNAs in CRC and the mechanistic axis of their regulation. 
6.5. Induction of hypoxia 
Hypoxia has always been studied in the context of cancer as it diverts 
the cellular energetics within the TME towards the survival and pro-
gression of cancer. Despite advocating malignancy, hypoxia even im-
pedes the efficacy of cancer therapies including immunotherapy [126]. 
Mounting evidence suggests that crosstalk between hypoxia and circR-
NAs aggravates the pathophysiology in the colorectal TME [127,128]. 
For instance, circ-ERBIN (ERBB2 interacting protein or ERBB2IP) trig-
gers enhanced expression of initiation factor 4E binding protein 1 
(4EBP-1) via sponging of miR-125a-5p and miR-138-5p, which in turn 
activates the translation of the hypoxia inducing factor-1 alpha 
(HIF-1-α), a master gene regulator of hypoxia [129]. Dysregulation of 
HIF-1-α pathway ultimately promotes angiogenesis, EMT, and metas-
tasis through direct regulation of ZEB1 in CRC [130]. Additionally, 
increased expression of oncogenic circRNA, circCCDC66, in 
hypoxia-induced CRC inhibited the expression of miR-3140 followed by 
enhanced autophagy to facilitate CRC progression [131]. Furthermore, 
hypoxia induces the upregulation of a prominent circRNA, circZNF292, 
independently of HIF-1-α. Besides, ZNF292 is a tumor suppressor gene 
and its overexpression promotes angiogenic sprouting in 
hypoxia-induced endothelial cells [132]. Moreover, frame shift muta-
tions in ZNF292 have been reported in several carcinomas including 
CRC [132]. Finally, prolonged hypoxia increases the abundance of 
circRNA, circ-133, in exosomes derived from hypoxia-induced CRC cell 
lines including SW480 and HCT116 [133]. However, the regulatory 
mechanisms of hypoxia in circRNA biogenesis are still not evident. 
Additionally, further understanding of downstream effectors of circR-
NAs in hypoxic colorectal TME is warranted to develop novel thera-
peutic approaches, which could target hypoxia and circRNA in CRC. 
6.6. Induction of tumor resistance to chemotherapy and radiotherapy 
Besides controlling the progression and metastasis of CRC, circRNAs 
can be also involved in modulating the sensitivity of tumor cells to 
therapy. Abu et al. identified several circRNAs which are differentially 
expressed in chemo-resistant and chemo-sensitive HCT116 cell line 
[134]. Authors reported that circ_103306 and circ_32883, derived from 
STAB1 (stabilin1) and EML5 genes, were significantly upregulated in 
CRC cells and capable of inducing drug resistance and immunosup-
pression via the interaction with miR-370-3p and miR-130b [134]. 
Similarly, higher expression of circHIPK3 in CRC tumor tissues revealed 
that it sponges miR-637 to upregulate STAT3 and activate bcl2/beclin1 
signaling pathway to mediate resistance to oxaliplatin (chemothera-
peutic agent) [135]. Another example is circ_001680, which induces 
irinotecan chemoresistance in CRC by sponging miR-340 and increasing 
the expression of BMI1, gene responsible for controlling cancer stemness 
[136]. CircCCDC66 (circ_0001313) has been reported to promote 
radiotherapy resistance in CRC by sponging miR-338-3P and suppress-
ing the action of caspase-3 during radiation [137]. Apart from this, 
circCCDC66 mediates chemoresistance through PI3KK-mediated DHX9 
phosphorylation and is highly expressed during oxaliplatin treatment 
[81]. Furthermore, there are many exosomes-derived circRNAs that 
mediate chemoresistance in several cancers including CRC [53,138]. 
Transcriptomic analysis of exosomal circRNAs in folfox-resistant HCT 
cells identified several dysregulated circRNAs [139]. CircRNAs in exo-
somes can be easily transferred from donor to recipient cells where they 
modulate gene expression and protein function and confer chemo-
resistance on target cells [138]. For instance, circ_0005963, which is 
present in exosomes derived from oxaliplatin resistant cells can reduce 
drug sensitivity after being transferred to oxaliplatin sensitive cells 
[140]. 
6.7. Modulation of anti-tumor immunity 
CircRNAs are also involved in the regulation of immune responses 
within the TME [141]. Wang et al. identified circ_100783 as being 
involved in the loss of CD28 during CD8+ T cell ageing through 
phosphoprotein-associated functions [142]. Later, microarray analysis 
in bone marrow-derived macrophages (BMDMs) indicated the contri-
bution of several circRNAs to macrophage differentiation and polari-
zation [143]. Meanwhile, the role of circRNAs in anti-tumor immunity is 
more evident by the detection of circ_0020397 in CRC cells, and its 
characterization as a tumor-promoting or oncogenic circRNA, involved 
in tumor invasion and progression [83]. Furthermore, circ_0020397 is 
elevated in CRC cells and sponges miR-138 to promote the expression of 
its target genes, TERT (telomerase reverse transcriptase) and PD-L1 [83]. 
Elevated expression of TERT gene supports cancer cells to bypass 
anti-growth signals and stimulate their proliferation [144], while PD-L1 
surface protein binds to its receptor PD-1 present on T cells resulting in 
the suppression of T cell activation and anti-tumor immune responses 
[145], and cancer progression [146]. Additionally, it has been reported 
that increased protein levels of PD-L1 can be driven by the action of ciR7 
in miRNA-independent fashion by modulating the expression of trans-
membrane proteins, CMTM4 and CMTM6 [147,148]. Alternatively, 
exosomes derived from CRC cells can induce differentiation of 
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peripheral blood CD4+ T cells to T regulatory-like cells via the activation 
of TGF-β1/Smad signaling and suppressing SAPK signaling [149]. This 
implies that more studies are demanded in this field to uncover the role 
of circRNAs in immune evasion. However, various roles of circRNAs in 
the colorectal TME including cell signaling, epithelial to mesenchymal 
transition, angiogenesis, tumor metastasis, drug resistance and tumor 
immune evasion are briefly depicted in Fig. 2. Collectively, these find-
ings suggesting the importance of identifying circRNAs that could serve 
as diagnostic or prognostic biomarkers for CRC and indicating the need 
to gain insights into the mechanistic roles of circRNAs within the colo-
rectal TME which suppress anti-tumor immunity and promote tumori-
genesis. This can be particularly helpful in advancing the screening of 
CRC and defining better therapeutic strategies to maximize clinical 
outcomes in CRC patients. 
7. Conclusions and future perspectives 
The involvement of oncogenic circRNAs in CRC invasion and 
metastasis has been well-studied and demonstrated using in vitro and 
preclinical models. Oncogenic circRNAs within the colorectal TME are 
capable of inducing cell cycle progression, stimulating signaling path-
ways which promote tumor cell proliferation/growth and EMT, and 
facilitating tumor resistance to chemotherapy and radiotherapy. How-
ever, further studies on the characterization of EMT-related circRNAs 
and identification of their mechanisms of action should provide better 
insights into potential treatment strategies for metastatic CRC. Alter-
natively, it is important to note that each oncogenic circRNA can have 
one or multiple target miRNA(s) and/or linear mRNA(s) to alter their 
expressions and exert a tumorigenic function. Therefore, targeting 
oncogenic circRNAs should be performed carefully taking the target 
miRNA and linear mRNA into considerations which is affected upon the 
inhibition of particular circRNA(s) [45]. Additionally, few circRNAs 
have been identified to take part in mediating immune evasion and 
angiogenesis. However, more studies are required to uncover more 
circRNAs (oncogenic or tumor suppressive), their functions and mech-
anisms of action in the colorectal TME. For instance, their effects on 
immune cells such as T cells, B cells, NK cells, MDSCs, macrophages and 
granulocytes should be defined, which has been already proven in other 
carcinomas. Moreover, circRNAs could serve as potential diagnostic or 
prognostic cancer biomarkers; however, further validation studies in 
Fig. 2. CircRNAs in the tumor microenvironment of colorectal cancer. (A) circFOXO3 and circ_0014717 suppress tumor cell proliferation by inducing cell cycle 
arrest. (B) circITCH inhibits Wnt/β-catenin pathway, while ciRS-7 inhibits EGFR/MAPK pathway leading to the suppression of tumor growth. (C) circ_001178 induces 
EMT through ZEB1, while circ_0009361 inhibits EMT by regulating APC2 expression. (D) circ_001680 mediates resistance to chemo drug, irinotecan, via upregulating 
BMI1 gene and circCCDC66 induces resistance to radiotherapy by suppressing caspase-3 activity. (E) CircVAPA and circACAP2 promote tumor invasion and 
metastasis through sponging miR-101 and miR-21, respectively. (F) circ_0020397 promotes immune evasion by increasing the expression of PD-L1 and TERT genes, 
while circ_100783 facilitates T cell ageing. (G) circ_001971 induces tumor angiogenesis by upregulating the gene expression of the proangiogenic factor VEGF-A. 
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large patient cohorts and examining their long-term follow-up clinical 
information [21,150]. 
Deeper insights into the functions of exosomal circRNAs in CRC are 
also required to further understand how they can mediate chemo-
resistance and convert effector T cells to Tregs within the TME. Up to 
date, majority of studies have reported the involvement of circRNAs in 
tumorigenesis through miRNA-mRNA transcriptional regulatory axis, 
while their functions after being translated into proteins have not been 
explored. The introduction of circRNA as promising cancer therapeutic 
agents could be advantageous given their stability and capacity of 
“sponging” miRNAs and proteins. However, additional investigations 
are required for the identification and characterization of more trans-
latable circRNAs, and their potential to encode tumor suppressor pro-
teins as a therapeutic strategy for cancer in the future. 
Although the scope of circRNAs in the field of translational medicine 
is getting widened, all these gaps of knowledge must be filled to provide 
novel insights into the role of circRNAs in CRC development and pro-
gression. Developing feasible therapeutic strategies to target oncogenic 
circRNAs include designing of exogenous siRNAs which complement 
target sites within the corresponding circRNAs. Alternatively, gene 
therapy could be employed to enhance the expression of tumor- 
suppressor circRNAs [31,151]. circRNAs could be directly applied into 
therapeutic regimens; however, extra cautions should be taken not to 
trigger immune-related adverse effects following the application of 
foreign circRNA [152]. 
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